Ph2/3 Etentamig+D Compared (DRd) NDMM Not Eligible for Transplant
Phase II/III Clinical Trial
M25-586: A Phase 2/3 Multicenter Randomized Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab Lenalidomide and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Participating Locations